Communiqués Achieve Life Sciences, Inc.

Actions

ACHV

US0044685008

Temps réel estimé Cboe BZX Autres places de cotation 21:39:45 26/06/2024			Varia. 5j.	Varia. 1 janv.
4,78 ^USD	+3,02 %		+0,21 %	+14,08 %

29/05	Achieve Life Sciences, Inc. Annonce le debut de l'essai clinique ORCA-OL evaluant l'exposition a long terme a la cytisinicline chez les personnes qui fument ou utilisent des E-cigarettes a la nicotine	CI
13/05	ACHIEVE LIFE SCIENCES, INC. : Oppenheimer persiste à l'achat	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors	29/05	AQ
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes	29/05	AQ
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be presented at Society of General Internal Medicine Annual Meeting	20/05	AQ
Achieve Life Sciences : Society of General Internal Medicine (SGIM) Annual Meeting	17/05	PU
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting	17/05	AQ
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update	09/05	AQ
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine	06/05	AQ
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024	25/04	AQ
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference	11/04	AQ
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update	28/03	AQ
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting	20/03	AQ
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024	14/03	AQ
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	06/03	AQ
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission	29/02	AQ
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement	29/02	AQ
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	11/12	AQ
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update	09/11	AQ
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023	26/10/23	AQ
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	03/10/23	AQ
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting	11/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Achieve Life Sciences, Inc.

Actions

ACHV

US0044685008

Communiqués

Filtres